Effect of comorbidities on response outcomes with first-line tyrosine kinase inhibitors (TKIs), dasatinib versus imatinib, in patients with chronic myeloid leukemia in chronic phase (CML-CP): Exploratory post hoc analysis of DASISION Meeting Abstract
| Authors: | Breccia, M.; Mauro, M.; Jabbour, E.; Saglio, G.; JimeĢnez-Velasco, A.; le Coutre, P.; DeGutis, I.; Khan, W.; Sy, O.; Swanink, R.; Cortes, J. E. |
| Abstract Title: | Effect of comorbidities on response outcomes with first-line tyrosine kinase inhibitors (TKIs), dasatinib versus imatinib, in patients with chronic myeloid leukemia in chronic phase (CML-CP): Exploratory post hoc analysis of DASISION |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | leukemia; dasatinib; tyrosine kinase inhibitor; chronic myeloid; first-line; comorbidities |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual event |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S326 |
| End Page: | S327 |
| Language: | English |
| ACCESSION: | WOS:000691910500204 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)01766-3 |
| Notes: | Meeting Abstract: CML-081 -- Source: Wos |
